QC
AUTL

Quadrature Capital’s Autolus Therapeutics AUTL Stock Holding History

Quadrature Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Buy
114,883
+60,150
+110% +$94.4K ﹤0.01% 1372
2026
Q1 		$75.5K Buy
54,733
+12,392
+29% +$18.8K ﹤0.01% 1257
2025
Q4 		$84.3K Sell
42,341
-314,922
-88% -$484K ﹤0.01% 1128
2025
Q3 		$582K Buy
357,263
+261,047
+271% +$510K 0.01% 485
2025
Q2 		$220K Buy
+96,216
New +$159K ﹤0.01% 786

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Quadrature Capital's AUTL Position: Q2 2026 in Review

Quadrature Capital increased its Autolus Therapeutics (AUTL) stake by 110% in Q2 2026, buying an estimated $94.4K and bringing the position to 114,883 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #1372.

Quadrature Capital first reported a position in AUTL in Q2 2025 and has held it in 5 quarters since. The position peaked at $582K in Q3 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Quadrature Capital held 114,883 shares of Autolus Therapeutics worth $184K as of Q2 2026.
  • Quadrature Capital bought 60,150 Autolus Therapeutics shares in Q2 2026, an estimated $94.4K.
  • Autolus Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1372 holding.
  • Quadrature Capital first reported a position in Autolus Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Autolus Therapeutics position peaked at $582K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.